Technical Analysis for GHDX - Genomic Health, Inc.

Grade Last Price % Change Price Change
grade F 54.18 -3.80% -2.14
GHDX closed down 3.8 percent on Friday, May 17, 2019, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical GHDX trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -3.80%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.80%
Calm After Storm Range Contraction -3.80%
NR7 Range Contraction -3.80%
Oversold Stochastic Weakness -3.80%
Calm After Storm Range Contraction -4.02%
Lower Bollinger Band Walk Weakness -4.02%
Outside Day Range Expansion -4.02%

Older signals for GHDX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company provides the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also offers the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer. Genomic Health, Inc. was founded in 2000 and is headquartered in Redwood City, California.
Medicine Cancer Healthcare Clinical Medicine Treatment Of Cancer Chemotherapy Breast Cancer Cancer Treatment Colorectal Cancer
Is GHDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 92.18
52 Week Low 36.94
Average Volume 547,965
200-Day Moving Average 68.3443
50-Day Moving Average 66.825
20-Day Moving Average 62.244
10-Day Moving Average 58.967
Average True Range 2.6391
ADX 38.01
+DI 9.1562
-DI 34.4177
Chandelier Exit (Long, 3 ATRs ) 60.0227
Chandelier Exit (Short, 3 ATRs ) 61.9873
Upper Bollinger Band 71.1201
Lower Bollinger Band 53.3679
Percent B (%b) 0.05
BandWidth 28.520339
MACD Line -3.2093
MACD Signal Line -2.4917
MACD Histogram -0.7176
Fundamentals Value
Market Cap 1.87 Billion
Num Shares 34.5 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -361.20
Price-to-Sales 3.41
Price-to-Book 6.72
PEG Ratio -149.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.41
Resistance 3 (R3) 57.73 56.97 56.87
Resistance 2 (R2) 56.97 56.15 56.81 56.69
Resistance 1 (R1) 55.58 55.64 55.20 55.26 56.51
Pivot Point 54.82 54.82 54.64 54.66 54.82
Support 1 (S1) 53.43 54.00 53.05 53.11 51.85
Support 2 (S2) 52.67 53.49 52.51 51.67
Support 3 (S3) 51.28 52.67 51.49
Support 4 (S4) 50.96